Skip to main content
Premium Trial:

Request an Annual Quote

Enpicom, DDL to Partner on Immunogenomics Sequencing, Analysis

NEW YORK (GenomeWeb) – Immunogenomics informatics company Enpicom and molecular diagnostics laboratory DDL said today that they would jointly develop an immune repertoire sequencing and analysis service. The two Dutch firms will market their product to organizations researching immune system-related diseases or developing drugs for immune disorders.

The partnership announcement comes less than a month after Enpicom launched IGX, a cloud-based repertoire sequencing data-analysis platform. Enpicom said in March that it had raised €1.2 million ($1.4 million) from a Series A investment round.

"Now we are also able to support organizations lacking the specific expertise or capabilities to perform repertoire sequencing with our smart new analysis and visualization methods," Enpicom CEO Jos Lunenberg said in a statement. "In DDL we have found a highly respected business partner with an excellent track record as molecular diagnostic testing laboratory for the biopharmaceutical industry."

DDL CEO Jan Lindeman said that the partnership would allow his company to expand its portfolio of MDx services to its pharmaceutical and biopharmaceutical clients. "ENPICOM's expertise and know-how are highly complementary to DDL's expertise and we are confident that this partnership will offer a unique opportunity to accelerate immunotherapy discovery and development," Lindeman said.